Abstract
The aim of controlled ovarian hyperstimulation (COH) for IVF is to produce multiple follicular development in order to harvest a suitable number of oocytes which can be fertilised and allow a selection of embryos which can be replaced into the uterus. Premature luteinisation is avoided by suppressing pituitary gonadotrophin production by co-treating with a GnRH agonist or antagonist, each with its own pros and cons. Individually tailoring the programme attempts to achieve the best live birth rates while taking into account the avoidance of ovarian hyperstimulation syndrome and the promotion of patient comfort, performed by utilizing several known facts such as ovarian response in any previous cycles, age, AMH or other predictors of ovarian reserve. The choice of gonadotrophin preparation for COH makes little if any difference regarding live birth rates while the antagonist is preferred over the agonist as regards patient comfort. Pre-treatment predictions of high, low and normal responders (using age, AMH and/or AFC) determines the protocol to be used and the starting dose of stimulation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
National Institute for Clinical Excellence Guideline. Fertility: assessment and treatment for people with fertility problems. 2004; 60–2. RCOG Press. ISBN 1-900364-97-2.
van Wely M, Westergaard LG, van der Veen F, Bossuyt PMM. Effectiveness of human menopausal gonadotrophin versus recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles: a meta-analysis. Fertil Steril. 2003;80:1086–93.
van Wely M, Kwan I, Burt AL, Thomas J, Vail A, van der Veen F, Al-Inany HG. Recombinant versus urinary gonadotrphin for ovarian stimulation in assisted reproductive technology cycles. Hum Reprod Update. 2012;18:111.
Harlin J, Aanesen A, Csemiczky G, et al. Delivery rates following IVF treatment, using two recombinant FSH preparations for ovarian stimulation. Hum Reprod. 2002;17:304–9.
Fleming R, Lloyd F, Herbert M, et al. Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone. Hum Reprod. 1998;13:1788–92.
Daya S, Gunby J, Hughes EG, et al. Follicle-stimulating hormone versus human menopausal gonadotrophin for in-vitro fertilization cycles: a mets-analysis. Fertil Steril. 1997;67:889–99.
Humaidan P, Bungum L, Bungum M, et al. Ovarian response and pregnancy outcome related to mid-follicular LH levels in women undergoing assisted reproduction with GnRH agonist down-regulation and recombinant FSH stimulation. Hum Reprod. 2002;17:2016–21.
Mochtar MH, van der Veen F, Ziech M, van Wely M, Musters A. Recombinant LH for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database Syst Rev. 2007;(2):CD005070.
The European Recombinant LH Study Group. Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotrophin in inducing final follicular maturation and ovulation in in-vitro fertilization procedures: results of a multicenter double-blind. J Clin Endocrinol Metab. 2001;86:2607–18.
Daya S. Gonadotropin releasing hormone agonist protocols for pituitary desensitization in in-vitro fertilization and gamete intra-fallopian transfer cycles. Cochrane Library, Cochrane Collaboration. 2000;(2). Oxford: Update Software.
Pellicer A, Simon C, Miro F, et al. Ovarian response and outcome of in-vitro fertilization in patients treated with gonadotrophin-releasing hormone analogues in different phases of the menstrual cycle. Hum Reprod. 1989;4:285–9.
Maheshwari A, Caserta D, Siristatidis CS, Bhattacharya S. Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database Syst Rev. 2011;(8):CD006919.
Oliviennes F, Diedrich K, Frydman R, Felberbaum RE, Howles CM, Cetrotide Multiple Dose International Study Group. Safety and efficacy of a 3 mg dose of the GnRH antagonist cetrorelix in preventing premature LH surges: report of two large multicentre, multinational, phase IIIb clinical experiences. Reprod Biomed Online. 2003;6:432–8.
Escudero E, Bosch E, Crespo J, Simon C, Remohi J, Pellicer A. Comparison of two different starting multiple dose gonadotropin-releasing hormone antagonist protocols in a selected group of in vitro fertilization-embryo transfer patients. Fertil Steril. 2004;81:562–6.
Al-Inany HG, Youssef MA, Aboulgar M, et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2011;(1):CD008046.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Homburg, R. (2014). Controlled Ovarian Stimulation for IVF/ICSI. In: Ovulation Induction and Controlled Ovarian Stimulation. Springer, Cham. https://doi.org/10.1007/978-3-319-05612-8_16
Download citation
DOI: https://doi.org/10.1007/978-3-319-05612-8_16
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-05611-1
Online ISBN: 978-3-319-05612-8
eBook Packages: MedicineMedicine (R0)